Our Pricing

Order Mounjaro NHS Weight Loss Injections Online

Published on: June 03, 2026

If you're looking to order Mounjaro NHS weight loss injections online, Cured Pharmacy offers a streamlined prescription service with transparent upfront pricing from £135.00 UK-registered prescribers, and discreet home delivery. Our clinical team assesses your eligibility through a free online consultation, ensuring safe and appropriate treatment aligned with MHRA guidelines.

How to Order Mounjaro Weight Loss Injections Online

Ordering Mounjaro online through Cured Pharmacy involves a three-step process designed to meet UK regulatory standards. First, you complete a free online consultation that takes under three minutes, providing your medical history and weight management goals. Our UK-registered prescribers review your assessment within hours, determining whether Mounjaro (tirzepatide) is clinically appropriate for you.

If approved, your prescription is sent to our GPhC-registered pharmacy (registration 9012511), where superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees dispensing. Your Mounjaro KwikPen is dispatched in 100% discreet packaging, typically arriving within 1-3 working days. All prescription medications require clinical assessment by a UK prescriber — there are no shortcuts to obtaining genuine Mounjaro safely.

Unlike walk-in services, our online model provides transparent pricing before you begin your consultation. You'll know the exact cost from £135.00 upfront, with no hidden fees or surprise charges after your prescriber review.

What Is Mounjaro and How Does It Work for Weight Loss

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed by the MHRA for weight management in the UK [1]. Unlike single-pathway treatments, tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, producing enhanced effects on appetite regulation, insulin secretion, and energy expenditure.

In the pivotal SURMOUNT-1 trial, participants receiving the highest Mounjaro dose (15 mg weekly) achieved an average body weight reduction of 22.5% over 72 weeks — substantially greater than placebo and comparable treatments [1]. The dual-agonist mechanism appears to produce superior metabolic effects compared to GLP-1-only medications, though individual responses vary considerably.

Mounjaro works by slowing gastric emptying, reducing appetite signals in the brain, and improving insulin sensitivity. Most patients notice reduced hunger and earlier satiety within the first two weeks, though maximum weight loss typically occurs between months 8 and 12 of treatment [2].

Clinical Evidence for Tirzepatide

The SURMOUNT clinical trial programme enrolled over 5,000 adults with obesity or overweight plus weight-related complications. Across multiple studies, tirzepatide demonstrated consistent superiority over placebo, with dose-dependent weight reductions ranging from 15% to 22.5% [1][2]. Importantly, these trials required participants to follow reduced-calorie diets and increase physical activity, reflecting real-world weight management approaches.

Cardiovascular safety data from the SURPASS trials showed tirzepatide did not increase major adverse cardiac events compared to placebo, an essential consideration for patients with obesity-related comorbidities [3]. However, like all GLP-1-based therapies, Mounjaro carries risks including gastrointestinal side effects and potential thyroid concerns, which your prescriber will discuss during assessment.

Mounjaro vs Wegovy: Comparing Weight Loss Injections

Both Mounjaro (tirzepatide) and Wegovy (semaglutide) are once-weekly injectable medications licensed in the UK for chronic weight management, but they differ in mechanism and clinical outcomes. Wegovy activates only GLP-1 receptors, while Mounjaro's dual GIP/GLP-1 action appears to produce greater average weight loss in head-to-head comparisons.

In a direct comparison trial, tirzepatide 15 mg resulted in 5.5 kg greater weight loss than semaglutide 1 mg over 40 weeks [4]. However, Wegovy offers lower starting prices and may be more suitable for patients who respond well to single-pathway GLP-1 therapy. Your UK prescriber will consider your medical history, previous treatment responses, and budget when recommending the most appropriate option.

Both medications require gradual dose escalation to minimise gastrointestinal side effects. Mounjaro typically starts at 2.5 mg weekly, increasing every four weeks to a maintenance dose between 5 mg and 15 mg. Wegovy begins at 0.25 mg, escalating over 16-20 weeks to 2.4 mg weekly. Neither medication should be considered a standalone solution — both work best alongside dietary changes and increased physical activity.

Which Treatment Is Right for You

Choosing between Mounjaro and Wegovy depends on individual factors including BMI, comorbidities, previous medication responses, and cost considerations. Patients with higher baseline BMI or those who haven't responded adequately to other weight loss treatments may benefit from Mounjaro's dual-agonist mechanism. Those seeking a more established treatment with longer real-world safety data might prefer Wegovy.

Your online consultation will assess eligibility criteria including BMI thresholds (typically ≥30 kg/m², or ≥27 kg/m² with weight-related complications), contraindications such as personal or family history of medullary thyroid carcinoma, and potential drug interactions. Our prescribers follow NICE guidance and MHRA licensing conditions when determining suitability for either medication.

Mounjaro Pricing and NHS Availability

Mounjaro is available through Cured Pharmacy from £124.99 for a four-week supply, with final pricing determined by your prescribed dose. While Mounjaro received NICE approval for NHS prescription in certain circumstances, access through NHS services remains limited due to budget constraints and strict eligibility criteria. Most UK patients currently access Mounjaro through private prescription services.

Our transparent pricing model means you see the exact cost before completing your consultation — no hidden fees or post-approval surprises. We guarantee the lowest prices in the UK for genuine, MHRA-licensed Mounjaro KwikPens sourced through legitimate pharmaceutical supply chains. All medications dispensed by Cured Pharmacy are UK-licensed products, never grey imports or unlicensed alternatives.

Some online services advertise lower headline prices but add consultation fees, delivery charges, or require expensive ongoing subscription models. At Cured Pharmacy, the price you see includes prescriber review, pharmacy dispensing, and discreet home delivery. Repeat prescriptions follow the same transparent pricing structure, with no obligation to continue treatment if you and your prescriber decide it's no longer appropriate.

Mounjaro Side Effects and Safety Considerations

The most common side effects of Mounjaro are gastrointestinal, affecting up to 30-40% of patients in clinical trials [1]. These include nausea, diarrhoea, vomiting, constipation, and abdominal discomfort, typically most pronounced during dose escalation phases. Most gastrointestinal symptoms improve within 4-8 weeks as your body adjusts to the medication.

More serious but rare risks include pancreatitis (inflammation of the pancreas), gallbladder problems, and potential thyroid tumours. Mounjaro carries a boxed warning regarding thyroid C-cell tumours observed in rodent studies, though human relevance remains unclear [5]. Your prescriber will screen for personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 before approval.

Hypoglycaemia (low blood sugar) is uncommon with Mounjaro alone but increases if you're taking other diabetes medications. Patients report injection site reactions in approximately 2-3% of cases, usually mild redness or itching that resolves quickly. If you experience severe abdominal pain, persistent vomiting, or signs of allergic reaction, stop treatment and seek immediate medical attention.

Managing Side Effects Effectively

To minimise nausea and gastrointestinal discomfort, eat smaller, more frequent meals and avoid high-fat foods, especially during the first weeks of treatment. Staying well-hydrated helps manage constipation, while ginger tea or over-the-counter antiemetics may reduce nausea if needed. Never increase your dose faster than prescribed — the gradual escalation schedule exists specifically to improve tolerability.

Our clinical team provides ongoing support throughout your treatment. If side effects become problematic, your prescriber can adjust your dose escalation schedule or recommend symptomatic management strategies. Some patients benefit from pausing at a lower dose for an additional four weeks before continuing escalation. Open communication with your prescriber ensures the safest, most effective treatment experience.

Alternative Weight Loss Treatments Available

If Mounjaro isn't suitable or you're exploring other options, Cured Pharmacy offers several MHRA-licensed weight loss treatments. Wegovy (semaglutide) provides once-weekly GLP-1 therapy with robust clinical evidence, while Saxenda (liraglutide) offers a daily injection alternative. For patients preferring oral medications, we stock Wegovy oral tablets and Orlistat-based treatments including Xenical, Alli, and generic Orlistat.

Orlistat works through a completely different mechanism, blocking approximately 30% of dietary fat absorption rather than affecting appetite hormones [6]. It's suitable for patients who cannot tolerate GLP-1 medications or prefer a non-injectable option. However, average weight loss with Orlistat is typically lower than with GLP-1 therapies, ranging from 5-10% of body weight when combined with dietary changes.

Your online consultation assesses which treatment best matches your medical profile, lifestyle preferences, and weight management goals. Some patients start with Orlistat or Saxenda before progressing to Mounjaro or Wegovy, while others may combine pharmacotherapy with behavioural interventions. No single treatment works for everyone — personalised assessment by UK prescribers ensures you receive the most appropriate recommendation.

Combining Treatments with Lifestyle Changes

All weight loss medications work most effectively alongside dietary modifications and increased physical activity. NICE guidelines recommend structured lifestyle interventions as the foundation of weight management, with pharmacotherapy as an adjunct for patients who haven't achieved sufficient results through lifestyle changes alone [7]. Mounjaro and similar medications facilitate adherence to reduced-calorie diets by reducing hunger and cravings.

Evidence suggests that combining GLP-1 therapy with behavioural support programmes produces superior long-term outcomes compared to medication alone. Our prescribers can provide guidance on realistic calorie targets, macronutrient distribution, and physical activity goals appropriate for your current fitness level. Sustainable weight loss typically occurs at 0.5-1 kg per week, though initial losses may be more rapid with Mounjaro.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Garvey, W. T., Frias, J. P., Jastreboff, A. M., et al. (2023). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet, 402(10402), 613–626. https://doi.org/10.1016/S0140-6736(23)01200-X [accessed 13 August 2026]
3. Sattar, N., McGuire, D. K., Pavo, I., et al. (2022). Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nature Medicine, 28(3), 591–598. https://doi.org/10.1038/s41591-022-01707-4 [accessed 13 August 2026]
4. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
5. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen: Summary of Product Characteristics. GOV.UK. Retrieved from https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency [accessed 13 August 2026]
6. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
7. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (CG189). NICE. Retrieved from https://www.nice.org.uk/guidance/cg189 [accessed 13 August 2026]
8. Wilding, J. P. H., Batterham, R. L., Davies, M., et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553–1564. https://doi.org/10.1111/dom.14725 [accessed 13 August 2026]
9. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
10. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
11. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on adherence to lifestyle modifications alongside pharmacotherapy.